M.D. Anderson Cancer Center - Recruiting 18 years or older. - A Prospective Randomized Phase III Trial to Compare Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) Versus Whole Brain Radiation Therapy (WBRT) for Patients With >3 Brain Metastases From Melanoma.
SRS; WBRT; Cognitive Function Tests; Questionnaires
UNC Lineberger Comprehensive Cancer Center - Recruiting 21 years or older. - A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases.
AbbVie - Recruiting 18 years or older. - A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer.
to-BBB technologies B.V. - Recruiting 18 years or older. - An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma..
2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks
Zhejiang Beta Pharma Inc. - Recruiting 18 years to 75 years. - A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases.
The Methodist Hospital System - Recruiting 18 years to 79 years. - Phase II Trial of Chemotherapy With Temozolomide in Combination With Topotecan for Central Nervous System (CNS) Metastasis of Solid Tumors.
Jiangsu Simcere Pharmaceutical Co., Ltd. - Recruiting 18 years to 75 years. - Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy for the Treatment of Patients With Brain Metastases.
Samsung Medical Center - Recruiting 18 years or older. - Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC).
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Study, Multicenter, Open-label, Evaluating Efficacy of Treatment With Sutentr (Sunitinib) in Patients With Previously Untreated or Recurrent Brain Metastases Originating From Renal Cancer.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer.